Puma Biotechnology (NASDAQ:PBYI) quickly plunged 25% after a court ruled that some patents are invalid in a longstanding patent dispute with AstraZeneca over cancer drug Tagrisso. US District Judge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results